I can't see $NUVL on the #Jefferies25 London agenda, so I presume they pulled out.
@Abby10Smalls @AaronRosenblum5 38% by Recist 1.1, all confirmed, not sure if by BICR or not $NUVL https://t.co/OTLPdjxZXW
$NUVL presses ahead in ALK, stock +10% despite waning data and liver tox worries. Via @ApexOnco -> https://t.co/pWOkE181mu
And here's why! $NUVL https://t.co/HjS5DoBWkl
Also this from $NUVL (not sure if disclosed before): enhanced monitoring for transaminase elevations and prompt dose interventions have been implemented in the protocol for the ph3 Alkazar trial.
...and here are my quick comps: $NUVL Alkove-1 data, phase 1 vs pivotal stage https://t.co/OVveaViy1Q
Here's the $NUVL comparison vs phase 1, from #ESMO24 https://t.co/dTTfAbZi52
Nuvalent $NUVL sees success for its second genetically targeted lung cancer drug https://t.co/BN2gjd1qR7 via @matthewherper
Also $NUVL presents at #Jefferies25 in London on Wednesday
$NUVL reveals ORR from pivotal stage of Alkove-1 is 31%. That's lower than 38% cited in phase 1 stage, but need to delve into details.
$NUVL neladalkib data from pivotal part of Alkove-1 in TKI pretreated ALK+ve NSCLC coming today at 6:30am ET
Who won #ESMO25 and who lost? Via @ApexOnco https://t.co/EWzHIIH1Ck $IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $ZLAB $RHHBY
Good morning biotwitter! If you're catching up with #ESMO25 here's what we've published over the weekend https://t.co/lzhy6k4Raz Stocks to watch this morning: $GMAB $CELC $IOBT $MRUS $INCY $RCUS $AVBP $SMMT $NUVL $IMTX $OLMA $CGEM
#WCLC25 press briefing schedule is out Sat 6 Sep: two iza-bren studies $BMY Sun 7 Sep: Harmoni $SMMT & Arros-1 $NUVL Tue 9 Sep: $CADL
#WCLC25 late-breaker & plenary preview, via @ApexOnco https://t.co/VJj3Bocr0A $SMMT $BMY $BNTX $NUVL $CGEM
And here's your handy $NUVL vs $NUVB X-trial comparison (note caveats) https://t.co/HgHxFZio6C
$NUVL tries to match $NUVB, but zidesamtinib has lost important ground in the front line. @ApexOnco take on the Arros-1 update, plus filing plans -> https://t.co/JG83lbhPkq
Today it's $NUVL's turn with its ROS1-selective inhibitor zidesamtinib. Arros-1 data out by PR at 6:30am ET, then investor call at 8am. $NUVB
$NUVB -10%, mkt cap $670m $NUVL +1%, mkt cap $5.5bn
@oncinvestor @BiotechObserver Meanwhile, this is what $NUVL claims for zidesamtinib https://t.co/UM18rwywwL
$NUVB still claiming that Ibtrozi (taletrectinib) is a "next-generation Ros1 inhibitor", but this is what the FDA says: $NUVL https://t.co/dWd3WYf0cJ
